The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Timothy J. Wilkin

Division of Infectious Diseases

Weill Medical College of Cornell University

New York

New York 10065; email:

[email]@med.cornell.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Division of Infectious Diseases, Weill Medical College of Cornell University, New York, New York 10065; email:. 2007 - 2012
  • Cornell HIV Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, Box 566, USA. ;. 2003 - 2008

References

  1. CCR5 Antagonism in HIV Infection: Current Concepts and Future Opportunities. Wilkin, T.J., Gulick, R.M. Annu. Rev. Med. (2012) [Pubmed]
  2. The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients. Wilkin, T.J., Ribaudo, H.R., Tenorio, A.R., Gulick, R.M. HIV. Clin. Trials (2010) [Pubmed]
  3. Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients. Wilkin, T.J., Su, Z., Krambrink, A., Long, J., Greaves, W., Gross, R., Hughes, M.D., Flexner, C., Skolnik, P.R., Coakley, E., Godfrey, C., Hirsch, M., Kuritzkes, D.R., Gulick, R.M. J. Acquir. Immune Defic. Syndr. (2010) [Pubmed]
  4. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. Wilkin, T.J., McKinnon, J.E., DiRienzo, A.G., Mollan, K., Fletcher, C.V., Margolis, D.M., Bastow, B., Thal, G., Woodward, W., Godfrey, C., Wiegand, A., Maldarelli, F., Palmer, S., Coffin, J.M., Mellors, J.W., Swindells, S. J. Infect. Dis. (2009) [Pubmed]
  5. When to start antiretroviral therapy?. Wilkin, T.J., Gulick, R.M. Clin. Infect. Dis. (2008) [Pubmed]
  6. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Wilkin, T.J., Su, Z., Kuritzkes, D.R., Hughes, M., Flexner, C., Gross, R., Coakley, E., Greaves, W., Godfrey, C., Skolnik, P.R., Timpone, J., Rodriguez, B., Gulick, R.M. Clin. Infect. Dis. (2007) [Pubmed]
  7. Anal intraepithelial neoplasia in heterosexual and homosexual HIV-positive men with access to antiretroviral therapy. Wilkin, T.J., Palmer, S., Brudney, K.F., Chiasson, M.A., Wright, T.C. J. Infect. Dis. (2004) [Pubmed]
  8. Antiretroviral therapy: when and what to start-- an American perspective. Wilkin, T.J., Gulick, R.M. Current. Hiv/aids. Reports (2004) [Pubmed]
  9. Antiretroviral Therapy: When and What to Start-- An American Perspective. Wilkin, T.J., Gulick, R.M. Curr. Infect. Dis. Rep (2003) [Pubmed]
 
WikiGenes - Universities